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Psychotropic Prescriptions in a Sample Including Both
Healthy and Mood and Disruptive Disordered
Preschoolers: Relationships to Diagnosis, Impairment, 
Prescriber Type, and Assessment Methods
Joan L. Luby, M.D., Melissa Meade Stalets, M.A., and Andy C. Belden, Ph.D.
ABSTRACT
Objective: Epidemiological data has shown that psychotropic medications are being prescribed
to preschoolers at increasing rates. The diagnostic context and functional impairment of these
preschoolers remains unknown. This investigation aimed to address these questions in a sam-
ple of preschoolers who were either without symptoms (healthy) or with mood and disrup-
tive disorders by assessing them using a structured diagnostic interview and measure of im-
pairment.
Method: Preschoolers aged 3.0 to 5.11 without symptoms and those with symptoms of mood
and disruptive disorders were recruited from primary care and daycare sites in the St. Louis
area to participate in a psychiatric evaluation that included information about psychotropic
prescriptions from community practitioners.
Results: Seven percent of preschoolers (n  19) out of a total sample of n  267 were pre-
scribed psychotropic medications. Fifty-two percent of preschoolers in the total sample met
criteria for an Axis I psychiatric disorder. Presence of an Axis I disorder was significantly re-
lated to psychotropic prescription (p  0.01). Among preschoolers who met criteria for an Axis
I disorder 12% received psychotropics (Dx/Rx group). The Dx/Rx group was more impaired
than those with a diagnosis who were not prescribed psychotropics (p  0.001). Among
preschoolers taking psychotropic medications, two failed to meet criteria for any Axis I dis-
order.
Conclusion: In this sample, most psychotropic medications were prescribed for impaired
preschoolers with an Axis I diagnosis. These findings shed some light on the prescribing
trends among mood and disruptive disordered preschoolers.
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INTRODUCTION
EPIDEMIOLOGICAL INVESTIGATIONS have re-vealed that psychotropic medications have
been prescribed to preschool aged children
over the last decade at rates that raise concern
when the fact that they have not been tested for
efficacy or approved by the Food and Drug Ad-
ministration (FDA) for use in this young age
group is considered (Coyle 2000). Prior studies
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also indicate that these prescribing trends have
been accelerating in the past five years (Pathak
et al. 2004; Rappley et al. 1999; Zito and Safer
2005; Zito et al. 2000). However, several im-
portant issues have yet to be addressed by the
investigations done to date, preventing a full
understanding of the key contributors and un-
derlying factors giving rise to the public health
problem. One issue is that most of the available
data describes patterns of psychotropic med-
ication prescribing in preschoolers enrolled in
Medicaid or other federal or state funded in-
surance programs (Rushton and Whitmire
2001; Zito et al. 2000). While these samples give
us a picture of psychotropic prescribing in spe-
cific subpopulations, they are not representa-
tive of the general population.
Another critical and unexplored issue in the
available pharmaco-epidemiological studies is
that the diagnostic context of these prescriptions
remains unknown. One exception to this is a
study that addressed prescriptions in relation to
symptoms in a preschool sample from a health
maintenance organization (DeBar et al.,2003).
Further, it is unclear whether appropriate diag-
nostic assessments were conducted and what
DSM-IV diagnoses if any, or types and degree
of functional impairment, were being targeted
by these prescriptions. A related factor that re-
mains unknown is the medical specialty and
training (e.g., general practitioner versus child
psychiatrist) of prescribing practitioners. Yet an-
other key question that needs to be addressed is
whether medications are prescribed before, af-
ter, or in conjunction with a trial of psychother-
apy or other psychosocial interventions in these
very young children. Obtaining information
about these issues would further clarify the na-
ture of the preschool prescribing trend and
could be useful to direct public health education
and intervention efforts necessary to minimize
and prevent inappropriate prescribing.
During the same period that these prescribing
trends have arisen, significant progress has been
made in the area of clarifying age-appropriate as-
sessment techniques and diagnostic nosologies
of mental disorders in preschool children (Task
force on research diagnostic criteria: Infancy and
Preschool 2003). However, it remains unclear
whether these age-appropriate methods and/or
diagnostic criteria are being utilized in the psy-
chopharmacologic treatment decisions for pre-
school populations. In addition, the efficacy of a
few early psychotherapeutic and behavioral
techniques for the treatment of specific preschool
onset disorders has now been established (e.g.,
Hood and Eyberg 2003; Faja and Dawson 2006).
The positive and in some cases enduring ame-
liorative effects of early interventions in these
specific areas suggests a possible window of op-
portunity for early intervention during the
preschool period. Based on these new findings
and current prescribing trends of psychotropic
medications to preschool-age children, there is a
clear need for additional information regarding
the use of psychotropic medications among this
young and potentially vulnerable and/or po-
tentially uniquely treatable age group.
The aim of this investigation was to explore
the rates and types of psychotropic medications
prescribed by community practitioners in a
sample of healthy or mood and disruptive dis-
ordered preschool children who had under-
gone a comprehensive research diagnostic as-
sessment. We also sought to investigate the
methods of clinical assessment used by these 
community practitioners as well as the recom-
mendation and use of psychotherapy in ad-
vance of psychotropic prescribing.
METHOD
Participants and procedure
Preschoolers between 3.0 and 5 years 11
months of age (5.11) were recruited from com-
munity pediatric or primary care practices and
preschools/daycares in the St. Louis metropol-
itan area for participation in a study of early
emotional development and mood disorders.
Participants were ascertained using the Pre-
school Feelings Checklist (PFC; Luby et al. 2004)
a validated screening checklist that identified
children with symptoms of depression and dis-
ruptive disorders as well as those without be-
havioral problems. To achieve an ethnically and
socio-economically diverse sample, a demo-
graphically broad range of primary care and
daycare settings in the St. Louis metropolitan
area was selected for participation in the study.
Approximately 6,000 checklists were distrib-
uted to the recruiting sites and from those n 
1,474 checklists were returned to the Washing-
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ton University School of Medicine (WUSM)
Early Emotional Development Program
(EEDP). Using the PFC, and previously estab-
lished thresholds, the study population was
over-sampled for preschoolers with mood and
disruptive symptoms. This was done by design
so that a large group of preschoolers with these
disorders could be obtained to facilitate the
main study aims, which were to investigate the
nosology of preschool mood disorders. Previ-
ous findings have illustrated that a score  3
on the PFC is highly sensitive and moderately
specific for mood disorders as well as moder-
ately sensitive for disruptive disorders (Luby
et al., 2004). Caregivers of preschoolers between
3.0 and 5.11 years of age and with a PFC score 
3 and  1, as well as those with a PFC scores 1
based on the presence of the symptom of anhe-
donia, were contacted by phone for a screening
interview. Those without anhedonia and a score
of 1 and those with a score of 2 were excluded.
Eight hundred and ninety-nine (n  899) care-
givers of preschoolers were contacted by phone
to establish if any exclusion criteria (e.g., neuro-
logical disorders, autistic spectrum disorders,
developmental delays) were present and that all
inclusion criteria were met. Those who met all
inclusion and exclusion criteria (n  416) were
invited for study participation and n  302
agreed and participated in the full assessment.
Trained research assistants (separate parent
and child interviewers) evaluated preschool
study participants and their primary caregivers
at WUSM EEDP. The study protocol was re-
viewed and approved by the Human Research
Protection Office. Prior to the evaluation, par-
ents gave informed consent, and the children
assented to the study protocol. Preschoolers
participated in a comprehensive evaluation of
developmental capacities and mental health
status in both dyadic and individual testing for-
mats. The primary caregiver (94% were bio-
logical mothers) was interviewed about their
child’s behaviors, emotions and development.
In addition, caregivers completed four self-re-
port take-home questionnaires.
For the purpose of this investigation, the pri-
mary caregivers of all preschool participants re-
ported to be taking psychotropic medications
were subsequently contacted by telephone. Ad-
ditional information about the specialty of the
prescribing practitioner as well as the method of
clinical diagnostic assessment was obtained. As-
sessment methods were categorized in the fol-
lowing way: a specialty preschool mental health
assessment was defined by the use of a multi-
session dyadic play format, a general child men-
tal health assessment was defined as being seen
by a child psychiatrist in a format typically used
for older children (without observations of
dyadic play) and no formal mental health as-
sessment was defined as being seen by a non-
mental health practitioner in a single office visit.
In addition, information about whether any
form of psychotherapy was recommended or
initiated prior to, or concurrent with, medication
prescription was also sought. For the purpose of
the following analyses, psychotherapy was de-
fined broadly as any treatment by a clinician that
focused directly on children’s behaviors and
emotions. This could include psychodynamic,
cognitive and/or behavioral therapies. It did not
include therapies such as physical therapy,
speech and language or occupational therapy.
These treatments were categorized as “develop-
mental therapies” and were considered sepa-
rately. Out of n  20 preschoolers who were
reported as receiving medication, n  18 partic-
ipants were successfully contacted by phone and
provided the requested information, n  2 could
not be contacted or failed to return calls.
Measures
Information about mental health, prescrip-
tions taken by the child, and treatment (i.e., de-
velopmental as well as psychotherapeutic) 
was obtained using the Health and Behavior
Questionnaire (HBQ; Armstrong et al. 2003) an
age-appropriate measure with established va-
lidity (Essex et al. 2002). The HBQ assessed
“regular” medication use defined as “taken
daily for at least one month.” This measure was
completed by caregivers prior to coming to the
EEDP. Trained interviewers who remained
blind to children’s diagnostic status adminis-
tered all other study measures. Preschoolers’
degree of impairment, ranging from no im-
pairment to severe impairment was established
using the Preschool Early Childhood Func-
tional Assessment Scale (PECFAS; Hodges
1994) an age appropriate measure of impair-
ment with established validity. The PECFAS is
rated by trained interviewers who achieve re-
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liability with an outside site using standardized
testing materials (Murphy 1999). The PECFAS
is rated on the basis of parental response to
probes about their child’s functioning. Items
are designed to address impairment in func-
tioning as a result of symptoms and address 3
contexts (home, school and community) and 
4 domains (behavior towards others, moods/
emotions, self-harm, thinking and communica-
tion). Parents were also interviewed exten-
sively by a trained interviewer about their
child’s moods and behaviors using the
Preschool Age Psychiatric Assessment (PAPA;
Egger et al. 1999), The PAPA is a comprehen-
sive age-appropriate semi-structured interview
with established construct validity and test-
re-test reliability (Egger et al. 2006). Diagnostic
modules of the PAPA contain developmentally
sensitive translations of relevant mental health
symptoms. Diagnoses were based on standard
computerized DSM-IV algorithms. For mood
disorders, symptom criteria only were used
(duration criteria were set aside). Preschoolers
in the study sample fell into the following di-
agnostic categories based on the application of
DSM-IV algorithms: Major Depressive Disor-
ders (MDD), Bipolar-I (BP), ADHD, Opposi-
tional Defiant Disorder (ODD), Conduct Disor-
der (CD) and Anxiety Disorders (alone and in
varying co-morbid combinations). Preschoolers
who did not meet criteria for any of these dis-
orders were categorized as healthy.
Data analysis
Chi-square analyses were conducted to test
for differences between psychotropic medica-
tion use and demographic characteristics such
as, age, gender, and gross household income.
An odds ratio was computed to examine the
expected increase in likelihood that children
who were taking psychotropic medication(s)
would have been diagnosed with a DSM-IV
Axis-I disorder in the current study. Next, de-
scriptive statistics (i.e., percentages) were cal-
culated to examine the proportion of children
taking certain classes of psychotropic medica-
tion in relation to diagnostic classification, pre-
scriber-type, and assessment method. To test
the likelihood that preschoolers taking psy-
chotropic medications had or were receiving
psychotherapy and/or developmental therapy,
odds ratio tests were calculated. Last, Mann-
Whitney and odds ratio tests were calculated
to examine expected differences between
preschoolers’ psychotropic medication use and
functional impairment. Functional impairment
was measured and tested as a dimensional as
well as dichotomous (i.e., severe versus not se-
vere functional impairment) variable.
RESULTS
Psychotropic prescriptions and 
demographic factors
Out of the total sample of n  302, n  35
were missing the pertinent prescribing infor-
mation due to failing to complete the HBQ
Thus, relevant data about psychotropic med-
ication use was available for n  267 preschool-
ers. There were no demographic or diagnostic
differences between preschoolers of caregivers
who completed the HBQ and those who did
not. The study sample had a diverse socioeco-
nomic and ethnic composition consistent with
the ethnic composition of the St. Louis metro-
politan area (see Table 1). Among the sub-sam-
ple with data about medication use, 7% (i.e.,
n  19 out of n  267) were reported to be tak-
ing psychotropic medication. Alpha agonists
(guanfacine and clonidine) were included as
psychotropic medications (although originally
designed for cardiac treatments) due to their
use (and some available investigations) in clin-
ical practice to control impulsivity in young
children. Gender was related to medication
use, 2 (df1, n  267)  6.09, p  0.01, with rates
of psychotropic medication use approximately
four times higher among boys than girls. Gen-
der was also related to meeting criteria for any
DSM-IV Axis I diagnosis (i.e., yes or no). Boys
were almost twice as likely to be diagnosed
with any Axis I disorder compared to girls. Age
was related to medication status, 2 (df2, n 
267)  8.40 p  0.01, with n  1, 3-year-old
child taking psychotropics (stimulant & alpha
agonist) compared to n  8, 4-year olds (n  1
stimulant and antipsychotic, n  1 alpha ago-
nist and antipsychotic, n  1 lithium and an-
tipsychotic, n  3 stimulants, n  1 antipsy-
chotic, n  1 alpha agonist,) and n  10,
5-year-old children (n  1 alpha agonist and
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antipsychotic, n  7 stimulants, n  2 antipsy-
chotics). Preschoolers’ age did not differ as a
function of diagnostic status (i.e., BP, MDD,
ADHD/ODD/CD, anxiety, and healthy) in the
sub-sample (n  267) included in these analyses.
When examining the presence or absence of a
DSM-IV Axis I disorder (but not taking into ac-
count specific disorders), results indicated the
presence of any Axis I disorder was significantly
related to psychotropic medication use, 2 (df1,
n  267)  11.25, p  .01. Preschoolers with a
DSM-IV Axis I diagnosis were almost 9 (CI 
1.954 to 38.182) times more likely to be taking
a psychotropic medication than those with no
DSM-IV Axis I disorder (see Table 2).
Psychotropic prescriptions and 
DSM-IV diagnosis
Of the children with a DSM-IV Axis I diag-
nosis according to parent report on the PAPA,
12% (n  17) were taking psychotropic med-
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TABLE 1. DEMOGRAPHIC CHARACTERISTICS OF THE STUDY SAMPLE
DSM No DSM
DX/RX DX/No RX DX/RX DX/No RX
n  17 n  123 n  2 n  125
Gender % (n)
Male 77% (13) 55% (68) 100% (2) 44% (54)
Female 23% (4)0 45% (55) X 56% (70)
Age in Years
3 6% (1) 32% (39) X 28% (35)
4 47% (8)0 40% (49) X 48% (60)
5 47% (8)0 29% (35) 100% (2) 23% (29)
Ethnicity (child)
White 59% (10) 47% (57) 50% (1) 65% (81)
Black 35% (6)0 43% (53) 50% (1) 39% (36)
Hispanic 6% (1) 4% (5) X 2% (3)
Asian or Pacific X 3% (3) X 2% (2)
Indian
Mixed racial X 3% (3) X 2% (2)
background
Caregivers’ education
No college 23% (4)0 20% (24) X 14% (17)
Some college 53% (9)0 42% (52) 50% (1) 31% (38)
4-year degree 6% (1) 20% (24) 50% (1) 26% (32)
Beyond 4-year degree X 4% (5) X 7% (8)
Professional degree 18% (3)0 15% (18) X 22% (26)
Marital status
Married 59% (10) 50% (61) 50% (1) 67% (83)
Separated X 4% (5) X 2% (2)
Divorced 12% (2)0 12% (15) X 4% (5)
Widowed X X X 2% (2)
Never married 29% (5)0 34% (41) 50% (1) 26% (32)
Income
0–$20,000 31% (5)0 29% (31) X 21% (24)
$20,001–$40,000 19% (3)0 21% (23) X 11% (13)
$40,001–$60,000 31% (5)0 16% (17) 50% (1) 17% (20)
$60,000 19% (3)0 34% (37) 50% (1) 51% (59)
DSM DX/RX  Diagnostic and Statistical Manual Diagnosis, diagnosis/prescription; DX/No RX  Diganos-
tic and Statistical Manual Diagnosis, diagnosis/no prescription; No DSM  No Diagnostic and Statistical Man-
ual Diagnosis
ication. Five children (29%) of those on med-
ications were prescribed two psychotropic
medications. Among those taking psychotropic
medications in the sample as a whole (n  19),
11% (n  2) did not meet diagnostic criteria for
any of the DSM-IV Axis I disorders assessed.
Of note, Autistic Spectrum Disorders (ASDs)
were not assessed and attempts were made to
screen out participants with ASDs (which was
an exclusion criterion for study participation).
Within the sub-group on medication, specific
psychotropic medications prescribed within
different diagnostic groups, are outlined in
Table 3. Of particular interest was that all
preschool participants taking an atypical an-
tipsychotic met DSM-IV symptom criteria for a
diagnosis of BP-1 with co-morbid MDD (see
Table 3). Conversely, 42% of preschoolers who
met symptom criteria for BP-1 had been pre-
scribed a psychotropic medication.
Psychotropic prescriptions and prescriber type
and assessment method
Among the n  19 preschoolers who were
taking a psychotropic medication, information
regarding type of prescriber was available for
18 children (prescriber type unknown for 1
combination prescription). Of these preschool-
ers, 33% (n  6: n  3 atypical antipsychotic,
n  2 stimulant, n  1 atypical antipsychotic
and alpha agonist combination) of the pre-
scriptions were written by child psychiatrists,
33% (n  6: n  5 stimulant, n  1 alpha ago-
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TABLE 3. DSM-IV DIAGNOSIS AND MEDICATION PRESCRIBED
ADHD MD/ADHD/ MDD/BP/
Healthy Anxiety MDD CD /ODD ODD 1 Disruptive* Total
(n  2) (n  1) (n  1) (n  1) (n  1) (n  2) (n  11) RX
Stimulant 2 0 1 1 1 2 5 12
Antipsychotic 0 0 0 0 0 0 7 7
Alpha Agonist 0 1 0 0 0 0 2 3
Lithium 0 0 0 0 0 0 1 1
Total n 2 1 1 1 1 2 11
*Within this group four children were taking two separate psychotropic medications concurrently
MDD  major depressive disorder; CD  conduct disorder; ADHD/ODD  attention-deficit/hyperactivity disor-
der/oppositional defiant disorder; MDD/ADHD/ODD  major depressive disorder/attention-deficit/hyperactivity disor-
der/oppositional defiant disorder; MDD/BP  major depressive disorder/bipolar disorder; RX  prescription
TABLE 2. VARIABLES ASSOCIATED WITH PSYCHOTROPIC MEDICATION
PRESCRIPTION DURING PRESCHOOL PERIOD
Odds ratio Confidence interval
Male gender 3.84** 1.24–11.90
55 months vs. 54 months 4.90** 1.58–15.21
In psychotherapy 46.46*** 13.95–154.70
Met criteria for BP-1 21.36*** 7.47–61.02
Met criteria for disruptive disorder (ADHD, ODD, CD) 7.73*** 2.49–24.04
Met criteria for any Axis I disorder 8.63** 1.95–38.18
**p  .01; ***p  .001
BP-1  bipolar 1; ADHD  attention-deficit/hyperactivity disorder; ODD  oppositional defiant disorder; CD 
conduct disorder
Note: Confidence intervals above and throughout this paper are large simply because the point estimates are large. If
one were to examine the log odds ratios of the gender and psychotherapy findings above, it becomes clear that distances
between the lower and upper ends of the interval in relation to the point estimate are very similar.
nist) were written by pediatricians, 22% (n  4:
n  2 stimulants, n  1 atypical antipsychotic
and alpha agonist combination, n  1 stimulant
and alpha agonist combination) by pediatric neu-
rologists and 11% (n  2: n  1 stimulant, n  1
stimulant and atypical antipsychotic combina-
tion) were written by nurse practitioners work-
ing in a child psychiatry office. Information
about the type of assessment received prior to
psychotropic prescription was available for n 
17 preschoolers. Nine (53%) caregivers re-
ported their child did not receive any formal
mental health assessment prior to being pre-
scribed medication. Six preschoolers (35%) re-
ceived a general child mental health assess-
ment and two preschoolers (12%) received a
specialized preschool mental health assess-
ment. All preschool subjects who received pre-
scriptions from their pediatrician or neurolo-
gist did not receive a formal mental health
evaluation (defined above). Among those who
were prescribed by a child psychiatrist n  4
received a general mental health assessment and
n  2 received a specialized infant/preschool
assessment. Both subjects (n  2) prescribed by
a nurse practitioner working under the super-
vision of a child psychiatrist received a general
mental health evaluation. Of note was that both
participants who received medications but who
did not meet criteria for an Axis I DSM-IV di-
agnosis based on the PAPA received their pre-
scriptions from a pediatrician. Regarding the
type of assessment conducted for this sub-
group, this data was missing from one and the
mother of the second preschooler reported re-
ceiving no formal psychiatric assessment. Both
medicated preschoolers without a DSM-IV di-
agnosis were boys (see Table 1).
Psychotropic prescriptions and psychotherapy 
and developmental therapies
Fifteen out of n  19 or 79% of preschoolers
taking psychotropic medications had previous
or current psychotherapy of some form. Within
the entire study sample (i.e., n  267) n  30
preschoolers had previously or were currently
participating in some form of psychotherapy
(broadly defined as described above). Pre-
schoolers in psychotherapy were 46.45 (CI =
13.952 to 154.704) times more likely to be pre-
scribed a psychotropic medication than
preschoolers who were not in psychotherapy.
Among the 2 preschoolers who were on med-
ication and did not meet criteria for a DSM-IV
diagnosis, 1 received no psychotherapy either
prior to or concurrent with the medication
treatment. Of the n  19 preschoolers pre-
scribed psychotropic medications, 16% (n  3)
had received some form of developmental ther-
apy (i.e., school resource room, speech/lan-
guage therapy, physical and/or occupational
therapy) in the last year.
Psychotropic prescriptions and 
functional impairment
Mann-Whitney U tests were conducted to
evaluate potential differences in preschoolers’
impairment scores in relation to psychotropic
medication use and the presence or absence of
a DSM-IV Axis I diagnosis. The first analysis
examined whether there was a significant dif-
ference in impairment between children pre-
scribed psychotropic medication versus not
taking medication among preschoolers with 
an Axis I diagnosis. Results indicated that
preschoolers who were prescribed psychotropic
medication and who had an Axis I diagnosis
had significantly higher impairment scores on
all seven subscales of the PECFAS as well as on
the PECFAS total impairment score, z  4.66,
p  0.0001, compared to preschoolers with an
Axis I diagnosis who were not prescribed psy-
chotropic medications.
To examine the likelihood that preschoolers
taking psychotropic medications would be
rated as severely impaired on the PECFAS
overall as well as within its seven subscales,
odd ratios were computed. Analyses indicated
that preschoolers who had been prescribed a
psychotropic medication were 11 (CI  3.48 to
32.25) times more likely to have been given the
most severe rating on one or more of the PEC-
FAS subscales compared to those not on med-
ication. Odds ratios (and confidence intervals)
for specific subscales are provided in Table 4.
Of particular interest was the finding that
preschoolers taking psychotropic medication
were 20 (CI  5.63 to 76.85) times more likely
to have been rated “severely impaired” on the
social subscale and 16 (CI  1.38 to 188.78)
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times more likely to have rated as severely im-
paired on the mood subscale.
Mann-Whitney U tests were conducted to
test whether preschoolers who were pre-
scribed an antipsychotic (in this study all
were atypical antipsychotics) were more im-
paired than preschoolers who were pre-
scribed any psychotropic medication outside
of this class (e.g., stimulant, alpha agonist,
other mood stabilizer). Results indicated that
preschoolers who were prescribed antipsy-
chotics were significantly more impaired on
the PECFAS home behavior (z  3.11, p 
0.005), social behavior (z  2.40, p  0.01),
moods/emotions (z  2.19, p  0.02), self-
harm (z  2.88, p  0.01), thinking/com-
munication (z  2.85, p  0.01) subscales, as
well as on the total PECFAS impairment scale
(z  2.78, p  0.01) compared to preschool-
ers prescribed psychotropic medication out-
side of this class.
DISCUSSION
Study findings report on psychotropic med-
ication use in a sample of preschoolers for
whom structured research diagnostic assess-
ments and measures of impairment have also
been obtained. These data provide new infor-
mation about the association between diagno-
sis from a validated age-appropriate semi-
structured diagnostic interview and level of
functional impairment and their relationship to
psychotropic medication use in specific diag-
nostic areas in preschool aged children. While
the available literature has consistently re-
ported high rates of psychotropic prescribing
to preschoolers, the available data to date have
not yet informed the issue of whether the chil-
dren receiving these prescriptions met criteria
for DSM-IV Axis I psychiatric disorders and if
so which disorders were the primary target of
treatment. Of note was the finding that 90% (17
out of 19) of preschoolers between the ages of
3.0 and 5.11 who were prescribed a psy-
chotropic medication met criteria for a DSM-IV
Axis 1 disorder based on an age appropriate
structured research diagnostic interview. In
keeping with these findings, preschoolers on
psychotropic medications had a much higher
likelihood of being rated as “severely im-
paired” on a structured measure. The highest
odds ratios for impairment were found in the
social and mood domains suggesting that dif-
ficulty in these areas may trigger pharmaco-
logic interventions.
Another clear and notable finding was the
higher rate of psychopharmacological treat-
ment of externalizing/disruptive behavioral
problems compared to those with internalizing
disorders only. In particular, psychopharma-
cologic treatment for preschoolers meeting
symptom criteria for BP-I (42% of those pre-
scribed a medication met symptom criteria for
BP-I), in which disruptive features are promi-
nent, was the highest of any disorder targeted.
Further, every atypical antipsychotic prescrip-
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TABLE 4. ODDS OF RATING OF “SEVERE” IMPAIRMENT BY DOMAIN MEDICATED VERSUS NOT MEDICATED
Odds ratios Confidence interval
School 11.78*** 3.09–44.960
Home 7.84*** 2.45–25.070
Community Did not occur Did not occur
Social 20.80*** 5.63–76.850
Mood 16.13** 1.38–188.77
Self-harm 3.69 (ns) 0.32–43.050
Thinking/communication 1.06 (ns) 0.943–1.200
**p  .01; ***p  .001
Note: Large confidence interval explanation as in Table 2.
tion written was for a child who met symptom
criteria for BP-I (in addition to other co-morbid
disorders). In contrast, no antidepressants were
prescribed in this preschool population that
contained n  72 (27%) preschoolers who met
all DSM-IV symptom criteria for MDD. This
difference in rates of prescribing antidepres-
sants compared to antipsychotics is of interest
because both classes of medications are simi-
larly lacking in safety and efficacy data for
preschool aged children. Several factors may
have contributed to the difference in prescrib-
ing of these two classes of medications, in-
cluding the under identification of depressive
syndromes and the recent FDA “Black Box”
warning for antidepressants. However, the so-
cially disruptive nature of the externalizing
disorders for which antipsychotics were pre-
scribed may be the most important factor. The
finding of one depressed preschooler who was
prescribed a stimulant medication was notable
along these lines. The disruptive disorders are
often viewed by caregivers and clinicians as re-
quiring greater urgency for behavioral control,
given the potential for self-harm and aggres-
sion towards others.
Another notable finding was the unique
characteristics of the two preschoolers who did
not meet criteria for a DSM-IV diagnosis but
who were prescribed stimulants. Both pre-
scriptions were written by pediatricians and at
least one was known to be administered with-
out formal psychiatric evaluations. Further
both participants were boys and one also re-
ceived psychotherapy. Notably, these two chil-
dren were significantly less impaired (accord-
ing to the PECFAS) compared to the n  17
preschoolers taking medications who also met
criteria for a DSM-IV Axis 1 disorder. It is pos-
sible that these children received clinical diag-
noses from their prescribing community prac-
titioner even though they did not meet criteria
for the DSM-IV diagnoses assessed as a part of
our research assessment. The use of stimulants
in both “undiagnosed” preschoolers suggests
that disruptive behavior that included inatten-
tion and/or impulsivity was being targeted.
Alternatively, it is also possible that medication
was effective in minimizing symptoms to a
point below diagnostic thresholds at the time
of the research diagnostic assessment. Based on
the very small number of children in this in-
teresting group, it is premature to draw con-
clusions. However larger scale studies that ad-
dress the relationship between diagnosis and
stimulant prescriptions among primary care
physicians would be of interest to investigate
this issue further.
Results suggest that the overall rate of psy-
chopharmacological treatment in the study
sample was comparable or lower than (when
sampling differences are considered) those re-
ported in population based samples. However,
this comparison is not straightforward based
on the fact that this study sample was over-
sampled for preschoolers with behavioral and
emotional symptoms and therefore is not a rep-
resentative community sample. Seven percent
(7%) of preschoolers in the study sample were
found to be on psychotropic medications. This
rate in a sample with high rates of psychiatric
disorders would seem to represent a lower rate
than the 5.9-6.3% prevalence rate of psycho-
tropics found in a recent population based
study of youths less than 20 years of age (Zito
et al. 2003). However, in a more targeted pre-
school-age Oregon HMO study of psychotropic
usage, 16% of a sample of 743 preschoolers 
was taking psychotropics (DeBar et al. 2003).
Based on differences in sampling characteris-
tics, it is difficult to compare this rate to the pre-
scription rate found in the study sample pre-
sented here.
Further, among preschoolers meeting diag-
nostic criteria for Axis I disorders (which in-
cluded ADHD, ODD, CD, MDD, BP and anx-
iety disorders) rates of prescribing in the study
sample were also lower than those reported in
preschool pharmacoepidemiology studies. For
example, among n  223 Medicaid enrollees in
Michigan younger than age 4 with a clinical di-
agnosis of ADHD, 57% took at least 1 medica-
tion (Rappley et al. 2002). This compares to only
22% of those with a diagnosis of ADHD based
on a structured research interview in the study
sample presented here.
The finding that boys are more likely to be
treated with psychotropic medication than
girls is consistent with previous findings in
larger and older samples (Shireman et al. 2005;
Rushton and Whitmire 2001) as well as in other
larger and younger Health Maintenance Orga-
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nization (HMO) samples (Zito et al. 2003).
These findings may be explained by the fact
that disruptive behaviors were the most com-
mon target of psychopharmacologic treatment,
and higher rates of disruptive behavioral dis-
orders have been found in preschool aged boys
(Egger and Angold, 2006).
Notably, preschoolers meeting DSM-IV
symptom criteria for BP-I (with other co-mor-
bid disorders) had the highest rate of psy-
chotropic medication use. While this diagnosis
remains highly controversial in preschool chil-
dren, preliminary evidence for the validity of
the BP-I syndrome has been previously pro-
vided (Luby and Belden 2006). This finding is
consistent with other findings from the same
study sample showing that this group demon-
strated the highest levels of impairment; levels
significantly higher even than those groups
with other Axis 1 disorders (Luby and Belden
2006). However, given the absence of prospec-
tive, double-blind, placebo-controlled studies
of treatment for preschool onset BP, this find-
ing suggests that prescriptions to preschoolers
with symptoms of mania and/or severe mood
instability may be an important source of 
the public health problem in preschool psy-
chotropic prescribing. These findings suggest
that studies of age-appropriate treatments, to
include both psychotherapeutic and psy-
chopharmacologic, as well as further studies of
the nosology of early onset BP are now needed.
The prescription of more than 1 psychotropic
medication to preschool children (found in 5
cases) is also of interest given the higher risks
involved and the paucity of data, not only on
use of single agents, but even further on the use
of combinations. Of note was that none of these
combination prescriptions was written by a pe-
diatrician. Although the sub-sample of pre-
schoolers on multiple psychotropic medications
was too small for further analysis in this sam-
ple, further investigation of this prescribing
practice would be of paramount importance.
Another issue apparent from the study find-
ings was the high rates of impairment found
among the group of children undergoing treat-
ment with a psychotropic medication. While
details of pre- and post-treatment impairment
are not known, and it is also unclear for how
long the study participants were treated be-
yond the 1 month period assessed by the HBQ,
this finding is notable. This finding taken to-
gether with other study findings and the extant
literature underscores the need for specific
study of the efficacy of these medications.
Several features of the study design and sam-
ple characteristics limit these findings. The rel-
atively small subgroup of preschoolers on psy-
chotropic medication on which many of the
analyses are based is a limitation. The reliance
of this small group suggests the reader should
interpret the findings with caution due to an
increased likelihood of statistical error, such as
a lack of power to identify potentially impor-
tant but small effect sizes. The fact that the
same rater conducted the psychiatric interview
(although was not privy to formal diagnostic
group classification) and the measure of im-
pairment could have given rise to rater bias.
The sole reliance on parent report to derive
psychiatric diagnosis without accounting for
observation of the child and child informant
measures is a design limitation. Another limi-
tation is the restricted focus on mood and 
disruptive disorders and the exclusion of
preschoolers with ASDs. The latter group is of
importance as preschoolers with ASDs are a
frequent target of psychotropic medications
and are worthy of independent study.
The nosology of many preschool disorders,
and internalizing disorders in particular, re-
mains understudied and substantial ambiguities
remain in the application of several psychiatric
diagnoses to preschool age children. Neverthe-
less, these findings from a diagnostically well-
characterized sample are informative and add
new details to the relatively small body of em-
pirical data regarding psychotropic medication
use in preschool age children. These findings un-
derscore the need for continued investigation in
this area. They also provide some reassurance
that based on standardized research assess-
ments, those children who meet criteria for Axis
I diagnoses and who are impaired appear to be
the primary targets of psychotropic treatment in
the community. Also reassuring was the major-
ity of preschoolers on psychotropic medications
were also in some form of psychotherapy. While
this does not confirm that these psychotropic
treatments were the optimal or even appropriate
treatments in each case, it does suggest that chil-
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dren who are symptomatic and impaired as a
group were being targeted in this sample of
mood and disruptive disordered preschoolers.
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